Search
Search Results
-
Aducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer’s disease
Aducanumab is a human immunoglobulin G1 monoclonal antibody that binds to the linear epitope formed by amino acids 3–7 of the Aβ peptide, with a...
-
Potential drugs for the treatment of Alzheimer’s disease
It is well known that amyloid precursor protein (APP), the enzyme β-secretase 1 (BACE1), cyclooxygenase 2 (COX-2), nicastrin (NCT), and...
-
Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease
Huntington’s disease (HD) is a paradigm of a genetic neurodegenerative disorder characterized by the expansion of CAG repeats in the HTT gene. This...
-
Amantadine extended release capsules (GOCOVRI®) in Parkinson’s disease: a profile of its use in the USA
Amantadine extended release (ER) [GOCOVRI ® ], an NMDA receptor antagonist, is an important treatment option in the management of levodopa-induced...
-
Using Liposomal and Intranasal Drugs and Pioglitazone for the Treatment and Prevention of Alzheimer’s Disease (Review)
This review article provides information on the development of liposomal drug delivery systems to cross the blood(brain barrier (BBB). Information on...
-
Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer’s disease
Alzheimer’s disease (AD) is a complex, progressive, neurodegenerative disorder. As with other common chronic diseases, multiple risk factors...
-
Application of 3D Whole-Brain Texture Analysis and the Feature Selection Method Based on within-Class Scatter in the Classification and Diagnosis of Alzheimer’s Disease
BackgroundPatients with mild cognitive impairment (MCI) are a high-risk group for Alzheimer’s disease (AD). Thus, a reliable prediction of the...
-
Preventive approach for overcoming dementia
Dementia is used as a general term to describe chronic disorders of mental processes caused by the deterioration of cognitive functions to the extent...
-
Clinical significance of fluid biomarkers in Alzheimer’s Disease
AbstractThe number of patients with Alzheimer’s Disease (AD) and other types of dementia disorders has drastically increased over the last decades....
-
Disease Modification in Alzheimer’s Disease: Current Thinking
Alzheimer’s disease (AD) has increasingly been recognized as a huge unmet medical need. Currently, there is no approved drug to cure, prevent, or...
-
Mobile Health Applications for Caring of Older People: Review and Comparison
BackgroundMobile devices and applications (apps) that act as access tools for health care management aid in the improvement of clinical decision...
-
Peroxisomal dysfunction in neurodegenerative diseases
Peroxisomes and their (patho-)physiological importance in heath and disease have attracted increasing interest during last few decades. Together with...
-
Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use
EGb 761 ® (Tanakan ® ) is a standardized extract of Ginkgo biloba leaves that has demonstrated protective properties against neuronal and vascular...
-
Defining an ‘older’ patient in the context of therapeutic decision making: perspectives of Australian pharmacists and nurses
ObjectiveOur aim was to explore Australian nurses and pharmacist’s perspectives on defining an ‘older’ patient in the context of decision making...
-
Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients
BackgroundNumerous statistically derived composite measures have recently been proposed as clinical outcome assessments (COAs) for clinical trials in...
-
Antidementiva
Größte Gruppe der Antidementiva sind die Cholinesterasehemmer gefolgt von Memantin, das aber nur etwa halb so viel verordnet wird. In beiden Gruppen...
-
Treating dementia with pharmacological options requires careful consideration of the potential benefits and risks
Dementia is a progressive disorder characterized by changes in behaviour, executive function, language, memory, personality and reasoning. Current...
-
Therapeutic strategies for Alzheimer’s disease in clinical trials
Alzheimer’s disease (AD) is considered to be the most common cause of dementia and is an incurable, progressive neurodegenerative disorder. Current...
-
Evaluación de las consecuencias socioeconómicas de la progresión de la enfermedad de Alzheimer en pacientes con demencia y deterioro cognitivo. Análisis exploratorio de la valoración de la eficacia de cinco medidas clínicas
ObjectiveThe primary objective of this analysis was to compare the performance of five alternative clinical measures as potential indicators of the...
-
Antidementiva
Größte Gruppe der Antidementiva sind die Cholinesterasehemmer gefolgt von Memantin, das aber nur etwa halb so viel verordnet wird. In beiden Gruppen...